Statins for major depressive disorder: A systematic review and meta-analysis of randomized controlled trials
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Background: The burden of depressive disorder is large and new treatment approaches are required. Repurposing widely available drugs such as statins may be a time- and cost-effective solution. Statins have anti-inflammatory and anti-oxidant properties which have been shown to be relevant to the pathophysiology of depression. This study assesses the efficacy, acceptability, tolerability, and safety of statins in major depressive disorder. Methods: Our study is an update and extension of a previous meta-analysis published in 2016 by Salagre et al. We performed a systematic review (PubMed/MEDLINE, Cochrane CENTRAL, ISI Web of Science, CINAHL, and ClinicalTrials.gov until the 1 st September 2020) and meta-analysis of randomized controlled trials using any statin against placebo or any other statin in the treatment of major depressive disorder. Our primary efficacy outcome measure was the mean value on any standardized scale for depressive symptoms at 8 weeks of treatment. We also calculated outcomes for efficacy, response, and remission at 2, 4, and 12 weeks, as well as acceptability (dropouts for any cause), tolerability (dropouts due to any adverse event), and safety (any adverse event) outcomes at the studies’ endpoints. Furthermore, we conducted an exploratory network meta-analysis for the primary efficacy outcome to identify potential differences between statins. Results: We retrieved five randomized controlled trials meeting our inclusion criteria: four used a statin in addition to an antidepressant and compared it to placebo plus antidepressant, and one compared two statins alone. and one comparing one statin with another. Statins compared to placebo in addition to antidepressants were efficacious at 8 weeks (N = 255, SMD = -0.48, 95% CI = -0.74 to -0. 22) and 12 weeks (N = 134, SMD = -0.47, 95% CI = -0.89 to -0.05, moderate certainty) with no difference for acceptability, tolerability, and safety (low certainty). An exploratory network meta-analysis suggested that the most lipophilic statins, especially simvastatin, could be more efficacious than less lipophilic or hydrophilic molecules. Conclusions: This systematic review suggests the efficacy, acceptability, tolerability, and safety of statins in addition to antidepressants in patients with major depressive disorder. Further clinical trials in different settings are required to test this result. Trial rgistration: PROSPERO registration: CRD42020170938.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig 1 Main statins’ lipophilicity. Lipophilicity is measured as C log P octanol/water, i.e. higher values correspond to higher lipophilicity. Note that simvastatin, lovastatin, and atorvastatin [29] are considered lipophilic statins, whereas rosuvastatin [30] is a highly hydrophilic statin.](https://figures.cochat.ai/paper-figures/4c54525f28574e6aafb0808103678fc2/statins-for-major-depressive-disorder-a-systematic-review-and-meta-analysis-of-figure-1.jpg)


![Fig 4 Forest plot for acceptability (number of participants discontinuing treatment [dropouts] due to any cause) and for tolerability (number of participants discontinuing treatment [dropouts] due to adverse events).](https://figures.cochat.ai/paper-figures/752c5574411349ce9aebfe614aba939e/statins-for-major-depressive-disorder-a-systematic-review-and-meta-analysis-of-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A meta-analysis of RCTs found that the addition of a statin to an antidepressant had a moderate effect on reducing depressive scores compared to placebo at week 8 and 12 with no report of serious adverse events across all trials (170).”
From Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories (2023) · cites this paper as [170]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“In the Sequenced Treatment Alternatives to Relieve Depression (STARD) study, just under half of the patients responded to first-line pharmacological therapy and one-third still experienced significant symptoms after four treatment steps over one year of treatment [3].”
BackgroundInflammaging: a new immune–metabolic viewpoint for age-related diseases
Franceschi, C., Garagnani, P., Parini, P., Giuliani, C., & Santoro, A. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0059-4 · Cited by 3,586 · cited 1×
“BMI, stress, chronic ailments), a concept known as “inflammaging” [51].”
BackgroundCipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857 · cited 2×
“Statins are considered safe drugs: more common side-effect include muscle pain or weakness, elevation of liver transaminases, nasopharyngitis, pharyngo-laryngeal pain, epistaxis, headache, and gastrointestinal disturbances; whereas more serious yet rare adverse events include rhabdomyolysis, new-onset diabetes mellitu…”
BackgroundRaison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617
Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms
Jain, M. K., & Ridker, P. M. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1901 · Cited by 915 · cited 1×
“These medications have significant anti-inflammatory and antioxidant effects that are rapid [10] and independent of their lipid-lowering properties [11].”
BackgroundNew insights into the pharmacodynamic and pharmacokinetic properties of statins
Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00045-5 · Cited by 796 · cited 1×
“Note that simvastatin, lovastatin, and atorvastatin [29] are considered lipophilic statins, whereas rosuvastatin [30] is a highly hydrophilic statin.”
BackgroundHow do antidepressants work? New perspectives for refining future treatment approaches
Harmer, C. J., Duman, R. S., & Cowen, P. J. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30015-9 · Cited by 616 · cited 1×
“Traditional antidepressants work in the main by modulating monoamine levels in the synaptic cleft [2] and are burdened by high rates of non-response.”
BackgroundSelf-citation
Research works printed but not linked: 1
- National Clinical Guideline C. National Institute for Health and Clinical Excellence: Guidance. Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. London: National Institute for Health and Care Excellence (UK) 25340243
Cited by
Hassamal, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1130989 · Cited by 578
“A meta-analysis of RCTs found that the addition of a statin to an antidepressant had a moderate effect on reducing depressive scores compared to placebo at week 8 and 12 with no report of serious adverse events across all trials (170).”
BackgroundYin, Y., Ju, T., Zeng, D., Duan, F., Zhu, Y., Liu, J., Li, Y., & Lu, W. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107322 · Cited by 179
Réus, G. Z., Manosso, L. M., Quevedo, J., & Carvalho, A. F. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105425 · Cited by 103
Du, Y., Dou, Y., Wang, M., Wang, Y., Yan, Y., Fan, H., Fan, N., Yang, X., & Ma, X. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1407529 · Cited by 66
Statins in Depression: An Evidence-Based Overview of Mechanisms and Clinical Studies
Giorgi, R. D., Pesci, N. R., Quinton, A. M. G., Crescenzo, F. D., Cowen, P. J., & Harmer, C. J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.702617 · Cited by 56
Self-citationTargeting Metabolic Dysfunction for the Treatment of Mood Disorders: Review of the Evidence
Jones, B. D. M., Farooqui, S., Kloiber, S. M., Husain, M. O., Mulsant, B. H., & Husain, M. I. (2021) · Life · doi:10.3390/life11080819 · Cited by 43
“…(10 mg) Aspirin (100 mg)or placebo DSM-IV MDD None MADRS, 12-week RCT no difference between rosuvastatin and placebo (−4.2, 95%CI (−9.1, 0.6), p = 0.089) Giorgi et al. 2021 Meta-analysis statins compared to placebo in 5 RCT at 8 weeks (N = 255, SMD = −0.48, 95%CI = −0.74 to −0.22)and 12 weeks (N =…”
BackgroundInfluentialVuu, Y. M., Shahib, A. K., & Rastegar, M. (2023) · Pharmaceuticals · doi:10.3390/ph16070914 · Cited by 36
The pharmacological bases for repurposing statins in depression: a review of mechanistic studies
Giorgi, R. D., Pesci, N. R., Rosso, G., Maina, G., Cowen, P., & Harmer, C. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02533-z · Cited by 27
Self-citationHypolipidemic Activity of Olive Oil-Based Nanostructured Lipid Carrier Containing Atorvastatin
Elsewedy, H. S., Shehata, T. M., Almostafa, M. M., & Soliman, W. E. (2022) · Nanomaterials · doi:10.3390/nano12132160 · Cited by 24
Husain, M. I., Chaudhry, I. B., Khoso, A. B., Kiran, T., Khan, N., Ahmad, F., Hodsoll, J. P., Husain, M. O., Naqvi, H., Nizami, A. T., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.0147 · Cited by 28
Dogaru, I.-A., Puiu, M. G., Manea, M., & Dionisie, V. (2022) · Brain Sciences · doi:10.3390/brainsci12101403 · Cited by 23
“This microbiota dysregulation-induced peripheral inflammation (with implications on the CNS, as previously discussed) is further augmented by the increase in intestinal permeability and ensuing bacterial translocation encountered in this condition [145].”
BackgroundInfluentialThe Role of Inflammation in Depression and Beyond: A Primer for Clinicians
Calagua-Bedoya, E. A., Rajasekaran, V., de Witte, L. D., & Pérez-Rodríguez, M. M. (2024) · Current Psychiatry Reports · doi:10.1007/s11920-024-01526-z · Cited by 20
“In regards to statins, a systematic review and meta-analysis of RCTs in MDD patients found that simvastatin, rosuvastatin lovastatin, and atorvastatin had potential anti-depressant effects and were well-tolerated [115].”
The effects of statin monotherapy on depressive symptoms: A systematic review and meta-analysis
Giorgi, R. D., Waters, S., Pesci, N. R., Rosso, G., Cowen, P. J., & Harmer, C. J. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.05.113 · Cited by 20
Self-citationSystematic reviews and meta-analyses on major depressive disorder: a bibliometric perspective
Chen, P., Feng, Y., Li, X.-H., Li, J., Wang, Y., Zheng, W.-Y., Su, Z., Cheung, T. C. C., Ungvari, G. S., Ng, C. H., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1136125 · Cited by 19
Lipids in major depressive disorder: new kids on the block or old friends revisited?
van der Heijden, A. R., & Houben, T. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1213011 · Cited by 16
“In the context of antidepressant sensitivity, cholesterol-lowering medication are currently in clinical trials as augmentation therapy for treatmentresistant depression (TRD) (89), though recent observations indicated no added effect of simvastatin on TRD (90).”
BackgroundXiao, X., Deng, H., Li, P., Sun, J., & Tian, J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1203444 · Cited by 17
Jahromi, G. G., & Rezaei, N. (2025) · Heart and Mind · doi:10.4103/hm.hm-d-24-00076 · Cited by 15
Otte, C., Chae, W. R., Dogan, D. Y., Piber, D., Roepke, S., Cho, A. B., Trumm, S., Kaczmarczyk, M., Brasanac, J., Wingenfeld, K., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0801 · Cited by 14
Giorgi, R. D., Martens, M., Pesci, N. R., Cowen, P. J., & Harmer, C. J. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211060307 · Cited by 14
“Both observational, epidemiological studies (Parsaik et al., 2014) and randomised clinical trials (Salagre et al., 2016) have suggested that statins may have clinically meaningful antidepressant effects (De Giorgi et al., 2021a).”
BackgroundResultSelf-citationGiorgi, R. D., Quinton, A. M. G., Waters, S., Cowen, P. J., & Harmer, C. J. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06156-y · Cited by 15
Self-citationGutlapalli, S. D., Farhat, H., Irfan, H., Muthiah, K., Pallipamu, N., Taheri, S., Thiagaraj, S. S., Shukla, T. S., Giva, S., & Penumetcha, S. S. (2022) · Cureus · doi:10.7759/cureus.32323 · Cited by 16
Jiang, J.-C., Hu, C., McIntosh, A. M., & Shah, S. H. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02403-8 · Cited by 16
Postolache, T. T., Medoff, D. R., Brown, C. H., Fang, L., Upadhyaya, S. K., Lowry, C. A., Miller, M. J., & Kreyenbuhl, J. A. (2021) · Pteridines · doi:10.1515/pteridines-2020-0028 · Cited by 12
“In comparing statins, simvastatin, the most lipophilic compound, demonstrated a stronger antidepressant capability than atorvastatin [62].”
BackgroundThe Possible Role of NLRP3 Inflammasome in Depression and Myocardial Infarction Comorbidity
Baysak, E., Yıldırım, Ç., Sayar, N., Sayar, M. K., Halaris, A. E., & Arıcıoğlu, F. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13091295 · Cited by 12
Xu, H., Du, Y., Wang, Q., Chen, L., Huang, J., Liu, Y., Zhou, C., & Biao, D. (2022) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2022.103394 · Cited by 13
Giorgi, R. D., Crescenzo, F. D., Cowen, P. J., Harmer, C. J., & Cipriani, A. (2023) · BMC Medicine · doi:10.1186/s12916-023-03138-5 · Cited by 11
Self-citationStatins in depression: a repurposed medical treatment can provide novel insights in mental health
Giorgi, R. D., Cowen, P. J., & Harmer, C. J. (2022) · International Review of Psychiatry · doi:10.1080/09540261.2022.2113369 · Cited by 10
“The clinical evidence above seems to suggest so (De Giorgi et al., 2021, 2022; Yatham et al., 2019), but the biological and psychological (Al-Asmari et al., 2017; Bhattarai et al., 2017; Kilic et al., 2012; Li et al., 2017; Ludka et al., 2014; Renshaw et al., 2009; Santos et al., 2012)…”
BackgroundResultInfluentialSelf-citationMichurov, D. A., Andreasyan, G. A., & Lozinsky, V. I. (2024) · Gels · doi:10.3390/gels10110734 · Cited by 9
Maes, M. H. J., Almulla, A. F., Stoyanov, D., & Zhang, Y. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2608029 · Cited by 10
van Bruggen, F. H., & McIntyre, R. S. (2025) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2025.101166 · Cited by 12
Alhazzaa, O. A., Abahussin, H. M., Majrashi, M. A., Alotaibi, M. S., Alkhrayef, M. N., Alhamdan, Z. A., & Alawad, A. O. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1743142 · Cited by 7
Lestari, P. M., Harahap, Y., Louisa, M., & Surini, S. (2025) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2025.02.001 · Cited by 5
Witkoś, J., Fusińska-Korpik, A., Hartman‐Petrycka, M., & Nowak, A. (2022) · PeerJ · doi:10.7717/peerj.13373 · Cited by 4
Effects of various statins on depressive symptoms: is there enough evidence?
Giorgi, R. D., Crescenzo, F. D., & Cowen, P. J. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.09.009 · Cited by 4
Self-citationThe metabolic mood: Cholesterol homeostasis as a convergence point for depression risk
Choe, M. S., & Park, I. (2026) · Developmental Cell · doi:10.1016/j.devcel.2025.12.008 · Cited by 2
Bojanić, I., Bjerkeset, O. A., Williams, L. J., Berk, M., Bjørngaard, J. H., Sund, E. R., & Sletvold, H. (2023) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1078 · Cited by 3
Płeska, K., Wojtania, J., Łepik, M., Uszok, Z., Rosiak, K., Reguła, K., Waloch, K., Piaszczyński, S., Czajka, A., & Szymański, B. (2024) · Quality in Sport · doi:10.12775/qs.2024.15.51715 · Cited by 1
“If it comes to menagement of depressive symptoms, studies show that lipophilic statins like atorvastatin, lovastatin, pitavastatin, simvastatin, and fluvastatin exert better results than hydrophilic statins like rosuvastatin and pravastatin (68).”
BackgroundHuo, J., Feng, L., Cheng, Y., Miao, Y.-L., Liu, W., Hou, M.-M., Zhang, H., Yang, C., Li, Y., Zhang, M., et al. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.111072 · Cited by 1
“Owing to the high blood – brain barrier permeability of simvastatin (De Giorgi et al., 2021), this study explored the therapeutic potential of simvastatin for TBI.”
BackgroundWaters, S., Giorgi, R. D., Quinton, A. M. G., Gillespie, A. L., Murphy, S. E., Cowen, P. J., & Harmer, C. J. (2023) · BJPsych Open · doi:10.1192/bjo.2023.44 · Cited by 1
“However, inconsistencies between preclinical 37,38 and clinical 37,39 – 43 evidence mean that their role in the management of depressive disorders remains unclear.”
Self-citationKhademi, A., Kamyab, P., Kouchaki, H., Kazemi, M., & Goharinia, M. (2025) · BMC Public Health · doi:10.1186/s12889-025-22993-w · Cited by 2
Neue und experimentelle medikamentöse Therapieverfahren
Mertens, L. J., Hart, X. M., Scharf, D., Spangemacher, M., & Gründer, G. (2022) · Springer eBooks · doi:10.1007/978-3-662-65734-8_11
The Role of Pharmacotherapy in the Management of Comorbidities
Bitter, I., Mohr, P., & Štuhec, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-81802-8_18
Giorgi, R. D., Waters, S., Gillespie, A. L., Quinton, A. M. G., Colwell, M., Murphy, S. E., Cowen, P. J., & Harmer, C. J. (2025) · Psychological Medicine · doi:10.1017/s0033291725001187 · Cited by 1
“The study completion rate, overall task adherence and data quality, and evidence of anticipated main effects of task condition were comparable to those seen for in-person laboratory studies (De Giorgi et al., 2021; De Giorgi, Quinton et al., 2022).”
InfluentialSelf-citationAssociations between statin use and depressive disorders and suicidal behaviour
Roztocka, A., Radziszewski, K., Osiński, P., Szlęzak, Z. A., Kulinek, A. J., & Stefaniak, I. (2025) · Psychiatria i Psychologia Kliniczna · doi:10.15557/pipk.2025.0017
Singh, K., Blostein, F., Wells, Q. S., Hodges, E. C., Cox, N. J., & Davis, L. K. (2025) · medRxiv · doi:10.1101/2025.10.13.25337946
Hassan, O., Selim, A., & Kassar, O. (2025) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2025.11.002
Aljaffer, M. A., Almadani, A. H., Alassiri, A. N., Almane, S. N., Basfar, A. A., Hakamei, Z. M., AlAhmari, Y. F., Alharbi, M. B., & Alghamdi, A. H. (2025) · Medicine · doi:10.1097/md.0000000000045607
Giorgi, R. D., Crescenzo, F. D., Cowen, P. J., Harmer, C. J., & Cipriani, A. (2023) · Figshare · doi:10.6084/m9.figshare.24522540
Self-citationEvolocumab intensive lipid-lowering therapy on prognosis of post-cerebral infarction depression
Yang, Y., Song, H.-Y., Zhang, M.-J., Wang, S.-G., & Liu, W.-G. (2026) · World Journal of Psychiatry · doi:10.5498/wjp.121270
Neuroinflammation in Major Depressive Disorder: Mechanisms, Biomarkers, and Therapeutic Implications
Włoszek, E., Mikołajek, B., Godlewska, A., Kocik, A., Wiak, B., Wywiał, A., Spaczyńska, K., Kropiwnicka, A., Racki, E., Motaouakkil, Y., et al. (2026) · African Journal of Biomedical Research · doi:10.69980/qy1sgw94
Simvastatin Mitigates Chemotherapy‐Induced Depressive‐Like Behaviors in Rats
Elbadawy, H. A., Ali, M. A. A. W., Badr, E., Gahin, S. G., El‐Naga, R. N., & Tolba, M. F. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70332
Metadata
- Authors
- De Giorgi, R., De Crescenzo, F., Rizzo Pesci, N., Martens, M., Howard, W., Cowen, P. J., & Harmer, C. J.
- Affiliations
- Warneford Hospital (GB)
- Oxford Health NHS Foundation Trust (GB)
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2021-03-30
- Volume
- 16
- Issue
- 3
- Pages
- e0249409
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC8009386
- OpenAlex
- W3145353625
- Cited by
- 52
- References
- 50
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 6 · 2023: 14 · 2022: 12 · 2021: 5
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Wellcome Trust (102176/Z/13/Z; grant: 216452/Z/19/Z)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- statins, major depressive disorder, drug repurposing, antidepressant augmentation, simvastatin, lipophilicity, depressive symptoms, treatment response and remission, safety and tolerability, anti-inflammatory effects of statins, adverse events, dropout rates, placebo comparison
- MeSH terms
- Antidepressive Agents, Major Depressive Disorder, Humans, Randomized Controlled Trials as Topic, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.